Tumor lysis syndrome following a single dose of capecitabine [7]

Annals of Pharmacotherapy

Volumn 38, Issue 5, 2004, Pages 902-

  Kurt, Mevlüt ^a   Eren, Orhan Önder ^a   Engin, Hüseyin ^a   Güler, Nilüfer ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL;

ADULT; BREAST CARCINOMA; CASE REPORT; CONFUSION; DYSARTHRIA; ECHOGRAPHY; FEMALE; GLASGOW COMA SCALE; HUMAN; LETTER; LOW BACK PAIN; MASTECTOMY; MULTIPLE ORGAN FAILURE; NAUSEA; PRIORITY JOURNAL; TUMOR LYSIS SYNDROME; VOMITING;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; TUMOR LYSIS SYNDROME;

EID: 1942534667     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D164     Document Type: Letter

References (4)

1. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-93.
2. Blum JL. Xeloda in the treatment of metastatic breast cancer. Oncology 1999;57(suppl 1):16-20.
3. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002;13:797-801.
4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.